ReviewJournal of Cancer2017
Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers.
Review in Journal of Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- A case report on imaging findings of rare segmental necrotizing granulomatous neuritis of leprosy involving ulnar nerve.Qatar medical journal · 2024Article
- Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients.Journal of cancer research and clinical oncology · 2023Article
- Oncolytic viruses for triple negative breast cancer and beyond.Biomarker research · 2021Review
- Presentation, Management, and Prognosis of Primary Gastrointestinal Melanoma: A Population-Based Study.The Journal of surgical research · 2021Article
- Immunotherapy in gastroesophageal cancers: Current state and future directions.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021Review
- Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.Journal for immunotherapy of cancer · 2020Article
- Article
- Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.Nature reviews. Gastroenterology & hepatology · 2018Review
- Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expansion of our understanding of tumor immunity and the recent success of new cancer immunotherapy has reignited the hope that we can treat cancer effectively with immunotherapeutic approaches. Immune checkpoint inhibitors have shown significant efficacy in the treatment of some solid and hematologic malignancies. Encouraged by recent success in some other types of malignancies, many clinical trials are ongoing to evaluate the efficacy of immune checkpoint inhibitors in gastrointestinal (GI) malignancies. In this review, we briefly discuss theoretical background and current status of immune checkpoint inhibitors in GI cancers. We summarize the key studies and present the ongoing clinical trials involving immune checkpoint inhibitors in GI cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.